Optas LLC Takes $220,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Optas LLC acquired a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 552 shares of the medical equipment provider’s stock, valued at approximately $220,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Baystate Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the period. MCF Advisors LLC grew its holdings in shares of Intuitive Surgical by 108.1% during the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the period. Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter worth about $28,000. Able Wealth Management LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Finally, Stone House Investment Management LLC grew its holdings in shares of Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Rubash sold 1,709 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total value of $649,420.00. Following the completion of the sale, the director now directly owns 16,051 shares in the company, valued at $6,099,380. The disclosure for this sale can be found here. Insiders have sold 17,956 shares of company stock valued at $6,927,011 over the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG stock traded down $0.26 on Friday, hitting $444.85. 3,106,192 shares of the stock traded hands, compared to its average volume of 1,372,778. The company has a market capitalization of $157.79 billion, a PE ratio of 80.30, a PEG ratio of 5.75 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $447.11. The company’s fifty day moving average is $403.83 and its 200 day moving average is $383.50.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.00 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target for the company. Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Citigroup upped their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, Stifel Nicolaus upped their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $403.67.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.